About Us
Development Journey
2023 - 2024
bThe grand plan has been realized
◆ New hypoglycemic drug, Senglitide, approved for marketing ◆ The only pharmaceutical innovation team in Suzhou, recognized as a "Double Creation" team in Jiangsu Province ◆ First close of C-round with over 100 million yuan in financing
2021 - 2022
beholding the sun blazing forth from a cloudy sky
◆The new antidiabetic drug, Senglitide, has completed Phase III clinical trials ◆ The first domestically produced rare disease drug approved for launch ◆ Four new anti-tumor drugs have been approved for clinical use, and two Sino US dual reports ◆ Awarded as a major innovation team in Suzhou
2020 - 2021
Milestones
◆ Submitting the application for approval of the first generic drug for rare diseases. ◆ The new hypoglycemic drugentering Phase III clinical trials with exemption from Phase II clinical trials. ◆ Jiangsu CGenePharmaceuticalCo Ltd was established.
2019 - 2020
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases. ◆ Completing Phase I clinical trial of a new hypoglycemic drug. ◆ Raising 150 million yuaninSeries A+ round financing.
2018 - 2019
◆ Raising nearly 100 million yuan in Series A round financing. ◆ Launching clinical trials of a Class 1.1 new hypoglycemic drug. ◆ Receiving funding from the national major special fund during the13th Five-Year period.
2016 - 2018
◆ Successfully obtaininginvestmentin SeriesPre-A round financing. ◆ Obtaining permissions forclinical trials of severalClass3.1 new drugs. ◆ Submitting applications for clinical study of a Class 1.1 new hypoglycemic drug.
Key Achievements
Science and technology projects
◆ “Major New Drug Creation” program under China’s13th Five-Year Plan
◆ “Major New Drug Creation” program under China’s 12th Five-Year Plan
◆ Project under Jiangsu Province Science and Technology Support Program
Qualifications
◆ Being included in the NurseryforCompany Listing
◆ Private Technology Enterprise
◆ Technology-based SME
◆ SuzhouMunicipal Engineering Technology R&D Center
Industry Leader
◆ State-levelleading talent
◆ Innovative and Entrepreneurial Talent of Jiangsu Province
◆ Leading Innovative and Entrepreneurial Talent of Suzhou
◆ Leading Talent of Suzhou Industrial Park
Achievements
◆ Accumulatively raising nearly 600 million yuan
◆ New hypoglycemic drug entering Phase III clinical trials with exemption from Phase II clinical trials
◆ The first generic drug for rare diseases has been approved to be released to the market
◆ Six IND approvals and 18 granted invention patents
Contact Information
Address: Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123
Tel： +86-512-62956960（Recruitment）
+86-512-62956961（marketing）
Copyright © 2022 CGeneTech (Suzhou, China) Co., Ltd.
在线客服添加返回顶部
页面顺滑的滚动
屏蔽页面上图片的alt/title提示
右侧在线客服样式 1,2,3 2
图片alt标题设置： Fland Environmental
表单验证提示文本： The content cannot be empty!
循环体没有内容时： Content is being organized—please wait!
CSS / JS 文件放置地